Back to Back Issues Page
AMD Research for a One Time Treatment
July 19, 2018

AMD Research for a One Time Treatment

All 18 patients of the Phase I study using RGX-314 have received their therapy for the treatment of wet age-related macular degeneration. “Completing enrollment of the third cohort in the Phase I clinical trial brings us one step closer toward delivering on the promise of a one-time treatment with rapid and sustained therapeutic effects for patients with wet AMD one of the largest indications for which gene therapy is being developed," states Stephen Yoo, M.D., Chief Medical Officer of REGENXBIO

Gene Therapy for AMD Treatment

Research using gene therapy to treat neovascular or wet macular degeneration works by delivering a gene that inhibits blood vessel growth. These abnormal blood vessels leak blood and fluid under the retina which distorts one's vision leading to several different types of vision changes including the loss of one's central or straight ahead vision.

Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO shares his enthusiasm for this AMD treatment: “RGX-314 has the potential to be a one-time treatment for people with wet AMD by delivering high expression of anti-VEGF antibodies through the use of our NAV AAV8 vector. We are pleased to share additional positive preclinical results, which were generated by our development partners at the University of Pennsylvania and Johns Hopkins ...”

How does gene therapy work and who is a candidate for this type of macular degeneration research? Find out more ...

Gene Therapy Research for Macular Degeneration

Leslie Degner, RN, BSN

Better Health for Better Vision

Back to Back Issues Page